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Epidermodysplasia verruciformis (EV)-type human papillomavirus (HPV) DNA have been detected by PCR in
squamous cell carcinomas (SCC) from both organ transplant recipients (OTR) and immunocompetent individuals.
Their role in skin cancer remains unclear, and previous studies have not addressed whether the viruses are
transcriptionally active. We have used in situ hybridization to investigate the transcriptional activity and DNA
localization of HPV. EV-HPV gene transcripts were demonstrated in four of 11 (36%) OTR SCC, one of two (50%)
IC SCC, and one of ﬁve (20%) OTR warts positive by PCR. Viral DNA co-localized with E2/E4 early region gene
transcripts in the middle or upper epidermal layers. Non-EV cutaneous HPV gene transcripts were demonstrated in
one of ﬁve (20%) OTR SCC and four of 10 (40%) OTR warts. In mixed infections transcripts for both types were
detected in two of six (33%) cases. Our results provide evidence of EV-HPV gene expression in SCC; although only
a proportion of tumors were positive, the similarly low transcriptional activity in warts suggests this is an
underestimate. These observations, together with emerging epidemiological and functional data, provide further
reason to focus on the contribution of EV-HPV types to the pathogenesis of cutaneous SCC.
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Human papillomaviruses (HPV) are highly species-specific
DNA tumor viruses whose life cycle is inseparably linked to
differentiation processes in pluristratified epithelia (Stanley
et al, 1994). These viruses achieve efficient dissemination
by infecting cutaneous and mucosal epithelia, stimulating
proliferation, and replicating in terminally differentiated ker-
atinocytes to cause benign warts. The association of certain
mucosal HPV, in particular, types 16, 18, 31, and 33, with
the genesis of anogenital carcinomas is well described, and
over 95% of carcinomas of the cervix are positive for HPV
DNA (Bosch et al, 2002). Viral genome integration and con-
sequent overexpression of the E6 and E7 oncoproteins are
associated with the inhibition of apoptosis via p53-depend-
ent and -independent mechanisms (reviewed in Thomas
et al, 1999).
An association of cutaneous HPV types 5 and 8 with
warty lesions and squamous cell carcinomas (SCC) occur-
ring in the sun-exposed skin of patients with the rare inher-
ited condition epidermodysplasia verruciformis (EV) led to
proposals that these viruses, designated EV types, may also
be oncogenic (Majewski and Jablonska, 1995). EV-HPV
gene transcription has been demonstrated in several skin
carcinomas from EV patients (Orth, 1987; Yutsudo and Ha-
kura, 1987; Yutsudo et al, 1994), suggesting that the virus is
biologically active in these lesions. The mechanisms by
which EV types might contribute to the development of cu-
taneous SCC, however, remain unclear. Unlike oncogenic
mucosal HPV, EV-HPV DNA persist extrachromosomally in
cancers, although there have been rare reports of integrated
viral DNA within metastatic EV tumors (Yabe et al, 1989). In
addition, EV-associated E6 proteins are unable to abrogate
apoptosis via the degradation of p53 (Elbel et al, 1997).
Instead, they may inhibit apoptosis by abrogating the func-
tion of BAK protein, a Bcl-2 family member expressed in
keratinocytes (Jackson et al, 2000).
PCR-based epidemiological studies have identified HPV
DNA in over 80% of immunosuppressed and 30% of
immunocompetent (IC) SCC; EV-HPV types are consistently
over-represented and multiple infections are frequently
present in immunosuppressed tumors (Harwood and Proby,
2002; Pfister, 2003). EV-HPV are frequently found in normal
skin, the likely reservoir being hair follicles, probably within
the stem cell niche (Boxman et al, 1997, 2000; Antonsson
et al, 2000). The presence of EV-HPV types in normal skin
and hair follicles has been linked in separate studies to an
increased risk of premalignant actinic keratoses (Boxman
et al, 2001) and invasive SCC (Struijk et al, 2003; Harwood1These two authors contributed equally to this work.
Abbreviations: EV, epidermodysplasia verruciformis; HPV, human
papillomavirus; IC, immunocompetent; ISH, in situ hybridization;
OTR, organ transplant recipient; SCC, squamous cell carcinoma
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et al, 2004). Seroepidemiological studies have also shown
an association between the prevalence of EV-HPV infection
and SCC risk (Bouwes Bavinck et al, 2000; Feltkamp et al,
2003; Masini et al, 2003). These data imply that EV-HPV
may play a role in the pathogenesis of SCC. Despite con-
siderable epidemiological data suggesting a causal associ-
ation, there are no studies addressing whether EV viruses
detected in these circumstances are localized to malignant
cells, nor whether they are transcriptionally active, both of
which would support a carcinogenic role. In order to ex-
amine this, we have used in situ hybridization (ISH) to es-
tablish the pattern of viral gene transcription and DNA
localization in benign and malignant organ transplant recip-
ients (OTR) and IC lesions that were positive by PCR for EV
and non-EV cutaneous HPV DNA.
Results
Viral gene transcription and DNA localization in benign
warts Viral gene expression was first examined in four be-
nign cutaneous warts from IC individuals. These lesions
were all positive by degenerate nested PCR for non-EV cu-
taneous HPV type 2. As expected from a previous study of
similar lesions (Peh et al, 2002), transcripts of both early and
late viral genes were detected (Table I), thereby confirming
the sensitivity of RNA-ISH for detecting HPV2 mRNA. DNA-
ISH demonstrated the presence of detectable HPV2 DNA
levels in all four samples (Table I).
PCR typing revealed that all 51 OTR warts contained
DNA from fully characterized HPV types; 13 of these were
selected for investigation of viral DNA and transcripts on the
basis of the availability of the appropriate HPV clones as
well as sufficient lesional tissue. These 13 samples har-
bored several different cutaneous types from both EV (HPV
20, 23, 24, 37 together with partially characterized se-
quences RTR  5 and  9) and non-EV (HPV 1, 2, 3, 7, 10,
27, 28, 41, 57, and 77) subfamilies (Table I) as well as, less
commonly, benign mucosal types (HPV 6, 11). DNA-ISH
demonstrated the presence of detectable levels of viral DNA
in six of seven warts (86%) tested with non-EV cutaneous
DNA probes (Table I). However, both samples tested with
Table I. HPV gene expression in viral warts
Warta Patient HPV typeb
K10
riboprobec HPV riboprobes testedd
Positive
riboprobes DNA probese
1 IC 2 þ 2E1, 2E2, 2E4, 2E6, 2E7, 2L1, 2L2 All 2/57 (þ )
2 IC 2 þ 2E1, 2E2, 2E4, 2E6, 2E7, 2L1, 2L2 All 2/57 (þ )
3 IC 2 þ 2E1, 2E2, 2E4, 2E6, 2E7, 2L1, 2L2 All 2/57 (þ )
4 IC 2 þ 2E1, 2E2, 2E4, 2E6, 2E7, 2L1, 2L2 All 2/57 (þ )
5 OTR 57 þ 2E2, 2E4, 2E6, 2E7, 2L1, 2L2 All 2/57 (þ )
6 OTR 3, 37 þ 3E1, 3E4, 3E7, 3L1 None 3/10 ()
7 OTR 10, 23, 57 þ 2E2, 2E4, 2L1, 2L2, 23E4, 23L1 None 2/57 (þ ), 3/10 ()
8 OTR 2, 11, 28, 41,
RTR  5
þ 2E2, 2E4, 2L1, 2L2, 6E4, 3E4 Faint 2E4,
faint 2E2f
2/57 (þ ), 3/10 (þ ),
6/11 ()
9 OTR 7, 20, 27 þ 20E4 None NT
10 OTR 11, 20 þ 20E4, 6E4 None 6/11 (), 20 ()
11 OTR 23, 27 - 23E4, 23L1 None NT
12 OTR 1, 27, 77, 23-related þ 77E7 None NT
13 OTR 2, 20 þ 2E4, 2E6, 2L2, 20E4 None NT
14 A OTR 20, 57 þ 20E4, 20E7, 2E4, 2L2 20E4, 2E4 2/57 (þ ), 20 ()
14 B OTR 3, 57 þ 3E4, 2E4 None 2/57 (þ ), 3/10 (þ )
14 C OTR 3, 57 þ 3E4, 2E2, 2E4, 2L2 None 2/57 (þ ), 3/10 (þ )
15 OTR 1, 27, 77 þ 77E7 None 2/57 (þ )
16 OTR 27, 77 þ 2E4, 77E7 Faint 77E7 2/57 (þ )
17 OTR 24, 27, 77, RTR  9 þ 77E7 None NT
IC, immunocompetent; OTR, organ transplant recipient; HPV, human papillomavirus; EV, epidermodysplasia verruciformis.
aSections from three separate areas of wart 14 were examined.
bHPV DNA detected by PCR typing. RTR  5 and RTR  9 sequences have not been fully characterized but belong to the EV-HPV superfamily. In
addition, one novel HPV sequence with closest homology to EV-HPV type 23 was detected.
cRiboprobes to keratin 10 were used to confirm the presence of mRNA. K10-negative samples were excluded from further analysis.
dHPV2 riboprobes were used to detect transcripts from types within the A4 subfamily (HPV 2, 27, and 57); HPV3 riboprobes were used to detect
transcripts from highly homologous HPV type 28; HPV6 riboprobes were used to detect transcripts from highly homologous HPV type 11.
eDNA probe mixtures were used as follows: 2/57 to detect types 2, 27, 57; 3/10 to detect types 3, 10, 28; 6/11 to detect types 6 and 11. Results
obtained with the probes are listed in parentheses. NT, no DNA probes were tested.
fResults were described as faint where it could not be excluded that staining was due to high background rather than low levels of specific signal.
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probes to EV-HPV type 20 proved to be negative, as did two
samples tested for mucosal types. In all cases, viral DNA
was localized in the middle or upper epidermis (Figs 1
and 2).
Expression of the positive control keratin 10 mRNA was
detected in all lesions with the exception of wart 11, which
was excluded from further analysis. Viral gene expression
was demonstrated in one of five samples (20%) tested with
EV-HPV antisense riboprobes and four of 10 samples (40%)
tested with non-EV cutaneous antisense riboprobes, al-
though in two of these four samples only a faint signal was
observed. Only one of three samples tested with both EV
and non-EV riboprobes showed evidence of co-expression
(HPV types 2 and 20, sample 14A, Table I). No staining was
observed using sense probes to the same transcripts,
thereby confirming that the signal represented genuine
RNA–RNA hybrids. Transcripts of both early and late viral
genes were detected (Table I, Fig 1). Viral gene expression
was greatest in the middle to upper epidermal layers, mir-
roring the pattern of viral DNA localization.
In one OTR wart (sample 14, Table I), three separate
sections of the lesions were available for analysis. HPV57
was present by PCR in all three sections, but sections B and
C additionally harbored HPV3 whereas HPV20 was detect-
ed in section A. Viral gene expression was detectable only
in section A, consistent with spatial variation in both HPV
types present and their expression within a single lesion.
Multiple sections of other warts and SCC were not exam-
ined in this manner, but it is plausible that such a variation
may also have been present.
Figure 1
In situ hybridization of viral wart 5. (a) DNA probe for human papillomavirus (HPV)2; antisense riboprobes for: (b) keratin 10; (c) HPV2 L1; (d) HPV2
E4; (e) HPV2 L2; (f) HPV2 E7.
Figure 2
In situ hybridization of viral wart 8. DNA probes for: (a) Human papillomavirus (HPV)2; (b) HPV3; (c) antisense riboprobe for HPV2 E4.
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Viral gene transcription and DNA localization in
SCC HPV DNA were identified by PCR in 63 of 84 (75%)
OTR SCC and six of 17 (35%) IC SCC; of these, 51 SCC in
total contained DNA from fully characterized HPV types.
From these samples, three IC and 15 OTR lesions were
selected for inclusion in the study on the basis of the avail-
ability of the appropriate HPV clones as well as sufficient
lesional tissue. No other specific selection criteria were
used. The majority of samples (16 of 18, 89%) harbored EV-
HPV DNA (types 5, 8, 14, 15, 19, 20, 21, 23 together with the
partially characterized sequences Z959969 and PSOX-1
and two novel EV-HPV sequences), although only one sam-
ple (SCC 4; Fig 3) demonstrated features suggestive of a
possible viral cytopathic effect (Majewski and Jablonska,
1995). The remainder contained only cutaneous non-EV
types (HPV 2, 3, 10, 27, and 77). Seven OTR SCC were co-
infected with both EV and non-EV types. Three samples
failed to demonstrate mRNA transcripts of the positive
control keratin 10 and were excluded from further analysis.
Of the remaining samples, viral gene expression was dem-
onstrated in one of two (50%) IC and four of 11 (36%) OTR
samples tested with EV-HPV antisense riboprobes and one
of five (20%) OTR samples tested with non-EV antisense
riboprobes. Only one of the three samples tested with both
EV and non-EV riboprobes showed evidence of co-expres-
sion (HPV types 3/10 and 15, SCC18, Table II and Fig 4).
Furthermore, in this sample only one of the two HPV types,
HPV15, demonstrated a strong signal, although the forma-
tion of mismatched hybrids between the HPV3 riboprobe
and HPV10 mRNA means that the level of HPV10 gene ex-
pression is likely to have been underestimated.
The specificity of all positive results was confirmed
by hybridization with the corresponding sense probes on
paired sections, which in all cases failed to produce a sig-
nal. As an additional control for specificity, as well as to
confirm the results obtained in SCC2, where transcripts
homologous to both HPV5 and HPV20 E4 riboprobes were
detected (Fig 5), the HPV20-positive SCC9 sample was ex-
amined with additional riboprobes to the E4 region of HPV
types 2, 3, and 5. As expected, only the 20E4 probe yielded
Figure 3
In situ hybridization (ISH) of squamous cell
carcinoma (SCC)4. Hematoxylin and eosin
staining of sections: (a) at low magnification
showing carcinoma in situ and invasive tumor;
(b) at high magnification showing an in situ
portion of this SCC that was contiguous with
the invasive component shown in (a). Some of
the cells have enlarged and pale-staining cy-
toplasm which might be keeping with a viral
cytopathic effect; ISH shows the carcinoma in
situ component using: (c) DNA probe for hu-
man papillomavirus (HPV)20; antisense (d) and
sense (e) riboprobes for HPV20 E4; antisense
riboprobes for (f), HPV20 E7; (g) HPV20 E6.
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a positive signal, thereby demonstrating that the stringency
of the hybridization protocol did not permit cross-reactivity
between EV types 5 and 20, which share 65% DNA se-
quence homology over the region targeted by the probes
(GenBank database).
Irrespective of HPV type, the highest levels of viral tran-
scripts were detected in the mid to upper epidermal layers,
with those homologous to the E4 riboprobe present in the
greatest abundance. These transcripts were designated E2/
E4 because it could not be excluded that some of these
Table II. HPV gene expression in SCC
SCC Patient HPV typea
K 10
riboprobeb HPV riboprobes testedc
Positive
riboprobes DNA probesd
1 IC 10  3E4 None NT
2 IC 5, 20, 12-related þ 5E4, 5E6, 5E7, 5L1, 20E4, 20E6, 20E7, 20L1 5E4, 20E4 5 (), 20 (þ )
3 IC 5, 21 þ 5E4, 5E7, 5L1 None 5 ()
4 OTR 3, 20, 23 þ 20E4, 20E6, 20E7, 20L1, 3E1, 3E4, 3E7,
3L1, 23E1, 23E4, 23E7, 23L1
20E4, 20E6, 20E7e 20 (þ ), 3/10 ()
5 OTR 5 þ 5E4 None 5 ()
6 OTR 5, 27, 77  77E7, 5E4 None NT
7 OTR 14, 77  77E7 None NT
8 OTR 10, 23 þ 23E1, 23E4, 23E7, 23L1 None 3/10 ()
9 OTR 19, 20 þ 20E4, 20E6, 20E7, 20L1, 5E4, 2E4, 3E4f 20E4 20 ()
10 OTR 14, Z95969 þ 14E4, 14E7, 14L1 None 14 ()
11 OTR 2, 3 þ 2E4, 2E7, 3E4, 3E7 None NT
12 OTR 20 þ 20E4, 20E6, 20E7, 20L1 None 20 ()
13 OTR 3, 14 þ 3E4, 3E7, 14E4, 14E7 None NT
14 OTR 3, Z95969 þ 3E4, 3E7 None 3/10 ()
15 OTR 5, 36-related þ 5E4, 5E6, 5E7, 5L1 5E4 5 (þ )
16 OTR 8, 20 þ 20E4, 20E6, 20E7, 20L1 None 20 ()
17 OTR 5, PSOX1 þ 5E4, 5E6, 5E7, 5L1 None 5 ()
18 OTR 10, 15 þ 3E4, 3E7, 15E4, 15E7, 15L1 Faint 3E4, 15E4g 3/10 (), 15 ()
IC, immunocompetent; OTR, organ transplant recipient; HPV, human papillomavirus; EV, epidermodysplasia verucciformis.
aHPV DNA detected by PCR typing. Z95969 and PSOX1 sequences have not been fully characterized but belong to the EV-HPV superfamily. In
addition two novel HPV sequences with closest homology to EV-HPV types 12 and 36 were detected.
bProbes to keratin 10 were used to confirm the presence of mRNA. K10-negative samples were excluded from further analysis.
cHPV3 probes were used to detect transcripts from highly homologous HPV type 10.
dResults obtained with the listed DNA probes are in parentheses. NT, no DNA probes were tested.
eStrong staining was obtained in the carcinoma in situ component but not the invasive region of the lesion.
fSample 9 was examined with probes to HPV types 2, 3, and 5 to examine cross-reactivity between EV-HPV types 5 and 20 and between HPV20 and
non-EV cutaneous types 2 and 3.
gResults were described as faint where it could not be excluded that staining was due to high background rather than low levels of specific signal.
Figure 4
In situ hybridization of squamous cell carcinoma 18. (a) Hematoxylin and eosin staining of section; antisense riboprobes for (b) human pap-
illomavirus (HPV)3 E4; (c) HPV15 E4.
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Figure 5
In situ hybridization of squamous cell car-
cinoma 2. (a) Hematoxylin and eosin staining
of section; (b) antisense riboprobe for human
papillomavirus (HPV)20 E4; antisense (c) and
sense (d) riboprobes for HPV5 E4.
Figure 6
In situ hybridization of squamous cell carcinoma 15. (a) Hematoxylin and eosin staining of section; DNA probes for: (b) human papillomavirus
(HPV)5, (c) negative control; antisense (d) and sense (e) riboprobes for HPV5 E4.
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transcripts might encode the overlapping E2 gene product
rather than E4. In four of the five positive SCC, transcripts were
detected throughout the lesion with only a moderate variation
in the level of gene expression in different areas. In SCC4,
however, considerable variability in gene expression was ob-
served and only the carcinoma in situ component demon-
strated abundant viral mRNA (Fig 3). Viral DNA were detected
by DNA-ISH in two of nine (22%) OTR and one of two (50%) IC
SCC tested with EV-HPV probes (Table II). In these positive
samples, HPV DNA was localized in the mid to upper epider-
mal layers concomitant with E2/E4 gene transcripts (Figs 3, 6).
All of the four samples hybridized with the mixed probe to non-
EV cutaneous types 3 and 10 were negative.
Discussion
This is a report of ISH used to localize EV-HPV DNA in warts
and SCC of both OTR and IC patients. We have demon-
strated gene transcripts of both EV and non-EV-HPV in a
proportion of lesions. EV-HPV transcripts were detected in
four of 11 (36%) SCC and one of five (20%) OTR warts. The
apparently low transcriptional activity in warts is likely to
reflect the sensitivity of the technique, which suggests that
the presence of transcripts in fewer than half of the OTR-
associated SCC may similarly be an underestimate. Taken
together, these data suggest that EV-HPV DNA is present
and transcriptionally active in some SCC outside the con-
text of EV.
Sensitivity/methodological limitations of ISH tech-
niques DNA- and RNA-ISH techniques were initially opt-
imized in IC HPV2-positive warts. Viral DNA localized to
lesional keratinocytes and all four samples were positive
with the seven HPV2 riboprobes tested (L1, L2, E1, E2, E4,
E6, E7), demonstrating, as would be expected in warts, a
high level of viral activity. DNA-ISH was positive for the
majority of OTR warts (six of eight, 75%), with transcription
demonstrated in only four of 12 (33%) lesions. Neither the
EV- nor the mucosal HPV-harboring warts tested were pos-
itive by DNA-ISH for those types, whereas EV-HPV tran-
scription was demonstrated in 20% (one of five). Overall,
therefore, DNA-ISH was positive in 83% (ten of 12) and
RNA-ISH in 50% (eight of 16) of warts. EV-HPV gene tran-
scripts were demonstrated in five of 13 (38%) SCC, but in
the majority only E2/E4 mRNA were detectable.
Apparent discrepancies between DNA- and RNA-ISH
data may be explained in several ways: (i) higher viral gene
expression in IC compared with OTR lesions, or higher viral
gene expression in HPV2-associated lesions compared with
those infected with other types; (ii) varying sensitivities of
the techniques used for detection of the different HPV e.g., if
RNA:RNA hybrids formed between HPV2 riboprobes and
transcripts have higher melting temperatures than hybrids
formed by EV-HPV and by other non-EV types, transcripts
would be more easily detected in HPV2-positive lesions
than others. Certainly, HPV2 riboprobes may prove rela-
tively insensitive at detecting HPV2-related types 27 and 57
because of the formation of mismatched RNA:RNA hybrids
with reduced melting temperatures; (iii) lower EV viral copy
number compared with non-EV copy number (and/or in-
creased sensitivity of the EV-PCR detection methodology),
such that the levels of viral mRNA other than E2/E4, if
present, were below the detection threshold of this tech-
nique; (iv) relative selectivity of transcripts sought in OTR
compared with IC lesions owing to a high frequency of
mixed infection, particularly with partially characterized and
novel EV types for which no probes are available; and (v)
regional variation in levels of gene transcription within le-
sions (as in wart 14), or a combination of these factors.
The apparently lower DNA- and RNA-ISH expression in
SCC compared with rates of HPV DNA PCR positivity may
also be partly explained by recent data suggesting that
such HPV positivity in tumor biopsies may reflect surface
contamination. Forslund and colleagues found that only six
of 18 (33%) of PCR-positive SCC remained positive after
tape-stripping of the lesional surface (Forslund et al, 2004),
a rate remarkably similar to our observation that HPV tran-
scripts were detectable in only 38% of HPV-positive SCC.
Our DNA- and RNA-ISH data may therefore be a more ac-
curate reflection of true HPV positivity in these tumors and a
means of identifying those tumors in which PCR positivity is
more likely to be biologically relevant.
Patterns of gene expression in benign and malignant
lesions Although EV-HPV mRNA were detected in fewer
warts than SCC (20% vs 38%, respectively), we observed a
comparable pattern of viral transcription in benign and ma-
lignant lesions. Overall, EV-HPV transcripts were detected
more frequently in SCC than warts whereas the incidence of
non-EV cutaneous HPV transcripts was higher in warts. In-
deed, the data obtained in the two types of lesion were
approximately inverted: 38% of SCC (four of 11 OTR and
one of two IC samples) displayed EV and 20% (one of five
OTR SCC) non-EV transcripts compared with 20% (one of
five OTR warts) and 40% (four of 10 OTR warts), respec-
tively, of warts.
A relatively high frequency of lesions harbored mixed in-
fection by PCR: nine of 13 (69%) OTR warts, seven of 15
(47%) OTR SCC but none of three IC SCC were positive for
both EV and non-EV-HPV DNA, in line with our previous
findings (Harwood et al, 1999, 2000). Despite this, only one
of three of warts and one of three of SCC tested displayed
transcripts from both EV and non-EV types, and in the case
of the SCC sample a strong signal was observed for the EV
type alone.
Our transcriptional data do not prove that HPV replica-
tion is occurring in SCC, although it does provide some
supportive evidence for this possibility. In this respect, our
findings of abundant E4 expression are relevant. E4 is now
thought to encode a late protein whose expression occurs
concomitantly with viral DNA replication (Rogel-Gaillard
et al, 1992; Doorbar et al, 1997). In agreement with this, we
found co-localization of E2/E4 mRNA with viral DNA in the
three SCC samples positive for EV DNA-ISH (Figs 3, 6).
Implications of these data for the role of HPV in cuta-
neous carcinogenesis Recent functional studies from our
laboratory and others have shown that E6 and E7 proteins
of SCC-associated HPV types display in vitro transforming
activity (Jackson et al, 2000, 2002; Caldeira et al, 2003;
Giampieri and Storey, 2004; Giampieri et al, 2004). Together
with recent epidemiological data (Bouwes Bavinck et al,
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2000; Feltkamp et al, 2003; Masini et al, 2003; Struijk et al,
2003; Harwood et al, 2004), these studies support a role for
EV-HPV in skin carcinogenesis. Until now, however, it has
not been clear whether the identification of HPV DNA in
these lesions represents active infection or merely reflects
the ability of sensitive PCR techniques to detect low copy
number latent infection.
In our series, EV-HPV E2/E4 transcripts were detected in
one of two (50%) IC and four of 11 (36%) OTR SCC, sug-
gesting that the presence of HPV represents active rather
than latent or ‘‘passenger’’ status. E6 and E7 transcripts
were found in only one OTR SCC, whereas in anogenital
cancer continued expression of E6 and E7 is required for
maintenance of the malignant phenotype (Bosch et al,
2002). However, there is no current evidence that the same
is true in HPV-positive SCC. The apparent absence of E6
and E7 transcripts in these lesions could alternatively reflect
the sensitivity of our ISH technique as E6 and E7 mRNA
may prove difficult to detect even in anogenital tumors
(Bohm et al, 1993). Finally, some authors have proposed a
‘‘hit-and-run’’ mechanism of action for HPV in skin carcin-
ogenesis in which HPV is required for initiation but not
progression of tumorigenesis, such that persistent viral
presence and expression of E6 and E7 would not be re-
quired (reviewed in Pfister, 2003).
In summary, this study has provided evidence of local-
ization of HPV DNA to malignant keratinocytes in SCC as
well as EV-HPV gene transcription in almost 40% of tumors,
although methodological limitations of the techniques used
suggest that this may be an underestimate. Taken together
with recent epidemiological and functional findings, these
data provide further reason to focus on EV-HPV in the
pathogenesis of cutaneous SCC.
Materials and Methods
HPV typing DNA was extracted from wart and SCC biopsies us-
ing QIAamp DNA Mini kits (QIAGEN, Crawley, UK) and HPV typing
undertaken using a panel of seven nested primers and one single
round primer pair as previously described (Harwood et al, 1999). In
total, 55 (four IC, 51 OTR) wart biopsies and 101 SCC (17 IC, 84
OTR) were HPV typed. Only samples containing HPV DNA from
one or more fully characterized types where cloned HPV were
available were selected (Tables I and II). Ethical approval for
this investigation was obtained from East London and City Health
Authority local ethics committee and the study was conducted
according to the Declaration of Helsinki Principles. All patients
participating in the study gave written, informed consent.
Riboprobe constructs and labelling of probes A non-radioac-
tive RNA-ISH protocol was carried out to study HPV gene expres-
sion. A human cytokeratin 10 riboprobe construct (a kind gift from
Dr P. Bowden, UWCM, Wales, UK) was used as a positive control
for the presence of genomic mRNA. HPV riboprobe constructs
were made by cloning DNA sequences from the relevant viral
genes into the polylinker site of pGEM 3Z or 4Z vectors in the
appropriate orientation to obtain sense and antisense transcripts
from the SP6 and T7 promoters, respectively. Riboprobe con-
structs were restricted to the most frequently detected HPV types,
not including partially characterized or novel HPV sequences. For
HPV77, a single E7 riboprobe construct was made as only a partial
genomic clone was available. The location of the riboprobes of
various types is shown in Fig 7. Digoxigenin-labelled riboprobes
were generated by the in vitro transcription of linearized template
DNA in the presence of digoxigenin-UTP using a DIG RNA labelling
kit (Roche, Mannheim, Germany). A series of 10-fold dilutions of
each riboprobe was spotted onto nitrocellulose membrane and
labelling efficiency was determined by immunological detection
using a DIG nucleic acid detection kit (Roche).
RNA-ISH ISH was performed on paraffin-embedded tissue sec-
tions of 5 mm. Sections were dewaxed in xylene, rehydrated
through an alcohol series, fixed in 4% paraformaldehyde, and par-
tially digested with 25 mg per mL Proteinase K for 10 min at 371C.
Sections were next re-fixed in 4% paraformaldehyde, treated with
0.25% acetic anhydride in 100 mM triethanolamine for 10 min at
ambient temperature, and dehydrated through an alcohol series
prior to incubation with 1 mL of appropriate riboprobe in 10 mL
hybridization buffer (10  SSC, 500 mM Tris pH 7.6, 50 mM
Na2HPO4, 50 mM NaH2PO4, 0.1% Ficoll, 0.1% polyvinyl pyrroli-
done) at 371C overnight. Sections were then washed at low strin-
gency (2  SSC/0.1% SDS) at 551C for 10 min, treated with 2 mg
per mL RNAse in 5  SSC at 371C for 10 min to remove unbound
probe, and washed at high stringency (0.1  SSC/0.04% SDS)
at 651C for 2  20 min. Subsequently, sections were incubated
with anti-digoxigenin alkaline phosphatase followed by the color
change reagent 5-bromo-4-chloro-3-indolyl phosphate and nitro-
blue tetrazolium salt (both from Roche) according to the manu-
facturer’s instructions. Sections were counterstained with aqueous
eosin, mounted in Faramount aqueous mounting medium (Dako,
Ely, UK), and the results were visualized by light microscopy. In
Figure7
Schematic representation of the location of subgenomic human
papilloma virus (HPV) riboprobes in the HPV genome. The start and
end nucleotide positions are shown for the various HPV types.
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developing the ISH protocol outlined above, several variables
including proteinase K digestion conditions, post-hybridization
washes, and methodology associated with visualization of bound
probe were optimized on IC wart samples to obtain the best signal
to background ratio.
As constructs were not available for all HPV types, HPV2 ribo-
probes were used to detect transcripts from related types 27 and
57, which share greater than 80% DNA sequence homology across
the regions targeted by the probes (GenBank database, National
Centre for Biotechnology Information, National Institutes of Health,
Bethesda, Maryland). Similarly, HPV3 riboprobes were used to
detect transcripts from the closely related HPV 10 and 28 (ap-
proximately 77% DNA sequence homology; GenBank database)
and HPV6 riboprobes used to detect HPV11 transcripts (greater
than 80% homology over the targeted region of the E4 gene; Gen-
Bank database). Whenever possible, samples were tested with a
complete panel of the relevant riboprobes but in cases of limited
tissue availability a subset, which always included the E4 ribo-
probe, was used. This was as a result of the observation that E4
transcripts were consistently present in greatest abundance, irre-
spective of HPV type. In order to exclude non-specific binding, all
sections were tested with both sense and antisense probes to
each viral gene of interest.
DNA probes and ISH DNA probes were made by the restriction
enzyme digestion of plasmids containing the complete genomes of
HPV types 2, 3, 5 6, 10, 11, 20, or 57. Linear HPV DNA was sep-
arated from plasmid DNA by agarose gel electrophoresis, purified
using the QIAquick gel extraction kit (QIAGEN), and labelled using
a DIG-DNA labelling kit (Roche) according to the manufacturer’s
instructions. Linearized plasmid DNA was labelled to make neg-
ative control probes. Labelling efficiency was determined as
described for riboprobes. DNA-ISH was performed on paraffin-
embedded sections as described for RNA-ISH with a few modi-
fications. Specifically, after rehydration through an alcohol series,
sections were incubated in 0.02 M HCl for 10 min, followed by
treatment with 3% H2O2 in phosphate-buffered saline (PBS) for
10 min and 0.01% Triton X-100 in PBS for 3 min instead of fixation
with 4% paraformaldehyde. Proteinase K digestion was performed
for 10 min using 500 mg per mL enzyme followed by two 5 min
washes in PBS containing 2 mg per mL glycine. Sections were then
treated in 20% acetic acid on ice for 15 s, fixed in 4% parafor-
maldehyde, and dehydrated through an alcohol series as for RNA-
ISH. Hybridization mixtures for each section comprising 1 mL probe
and 9 mL hybridization buffer were boiled for 1 min to denature
probes prior to addition to sections. Sections were then incubated
at 801C for 10 min prior to overnight incubation at 301C. Post-
hybridization washes were performed for 10 min each in: 2  SSC
at 501C, 0.2  SSC at ambient temperature, and at 421C and
0.1  SSC at ambient temperature. Signal was amplified using the
TSA Plus DNP-AP system (Perkin-Elmer, Boston, Massachusetts)
according to the manufacturer’s instructions. Sections were incu-
bated with color change reagent and visualized as for RNA-ISH. As
constructs were not available for all HPV types: DNA probe mix-
tures were used as followed: HPV2/57 to detect closely related
type 27; and 3/10 to detect closely related type 28. As for RNA-
ISH, the above protocol was developed by optimizing conditions
using IC wart samples.
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